Buckpitt-phase i single ascending dose study-BPN-19186 (EC5026) protocol development and finalization and database build and bioanalytical methods development for clinical trial execution
Ended Awarded Last action
- Contract number
- 75N95019F00089
- Awardee
-
PPD Development LP UEI ZANENSW6C665
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,820,177
Award facts
- Opportunity
-
- NIHNINDS1501 Solicitation number
- Phase I Clinical Trials for Development of Neurotherapeutics Award Notice · Posted Jun 18, 2015
- Contract value 89% obligated
-
- $1,820,176.69 Current, with exercised options
- $2,048,931.69 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Funding agency
- National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Cape Fear, NC 28401, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$271,629 | |
| Funding Only Action | -$1,156 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $117,900 | |
| Exercise an Option | $1,588,033 | |
| Original award | $387,029 |
About this award
This federal contract award is for a delivery order under an Indefinite Delivery/Indefinite Quantity (ID/IQ) parent award for Phase I clinical trials for the development of neurotherapeutics. The contract, valued at $2,048,931.69, was awarded to PPD Development LP, a global contract research organization (CRO) and subsidiary of Thermo Fisher Scientific. The work involves protocol development and finalization, database build, and bioanalytical methods development for clinical trial execution. This award is funded by the National Institute of Neurological Disorders and Stroke (NINDS), a civilian agency within the National Institutes of Health (NIH). The contract does not have a set-aside designation and is set to expire on June 30, 2026.
Quick answers
Who was awarded contract 75N95019F00089?
75N95019F00089 was awarded to PPD Development LP by National Institute on Drug Abuse (National Institutes of Health) on July 1, 2019.
How much is contract 75N95019F00089 worth?
The government has obligated $1,820,177 on 75N95019F00089. Its potential value, with all options, is $2,048,932.
Which agency awarded contract 75N95019F00089?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95019F00089, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).
Is contract 75N95019F00089 an order under another contract?
Yes. 75N95019F00089 is a delivery order under HHSN271201600005I, an indefinite delivery contract, on Phase I Clinical Trials for Development of Neurotherapeutics.
Was contract 75N95019F00089 competed?
The extent of competition for 75N95019F00089 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award